Therapeutic Potential of Naive Hair Follicle Stem Cells in Alzheimer’s Disease: A Comprehensive Evaluation of Neuroprotection and Neurogenesis Authors: Lina Liu, Dan Yang, Jin Fu Published: 2026 ABSTRACT BackgroundAs a highly prevalent neurological condition, Alzheimer’s disease (AD) imposes considerable economic pressure on global societies. Its core pathological feature is progressive degeneration within the central nervous system (CNS), a feature which establishes it as the leading trigger for dementia worldwide. Currently available therapies for AD are largely palliative and lack restorative efficacy. While stem cell transplantation holds promise for brain regeneration, the shortage of transplantable neural stem cells and ethical constraints remains a significant limitation. Hair follicle stem cells (HFSCs) are easily accessible, proliferative, low immunogenicity, and free of ethical concerns, making them an ideal candidate for neurodegenerative disease therapy. However, the application of naive, unmodified HFSCs in AD therapy has not been thoroughly explored. In contrast to our previous study using NGF-modified HFSCs, the present study used unmodified naive HFSCs to systematically evaluate their therapeutic effects in AD rats, focusing on neurogenesis, synaptic protection, and microglial polarization. Therefore, the present assessment sought a more complete understanding of HFSCs’ intrinsic therapeutic potential.MethodsWe induced AD in rats via intrahippocampal injection of Aβ1–42. Fourteen days post-modeling, HFSCs were stereotaxically transplanted into the hippocampal region of AD rats. Learning and memory were assessed using the Morris water maze test, and neuronal damage was evaluated by Nissl staining. Synaptic protein levels were measured by Western blot and immunohistochemistry. The same staining approach was used to assess hippocampal neurogenesis and quantify Iba-1‑positive microglia. Moreover, qPCR was performed to measure mRNA levels of key pro‑inflammatory and anti‑inflammatory factors.ResultsHFSCs transplantation not only markedly upregulated the synaptic proteins SYP and PSD-95, but also promoted neurogenesis and alleviated microglial overactivation in the AD rat hippocampus.ConclusionHFSCs represent a highly promising therapeutic strategy for AD. When delivered via transplantation, these cells protect against synaptic and neuronal injury, boost hippocampal neurogenesis, and prevent abnormal overactivation of microglia in the cerebral tissues of AD model rats. Together, these results offer comprehensive preclinical proof of the intrinsic therapeutic potential of unmodified HFSCs, distinguishing it from previous studies using genetically modified cells and laying a solid foundation for future clinical translation. Introduction Alzheimer’s disease (AD) is a progressive neurodegenerative condition affecting the CNS that primarily impacts older adults and pre-elderly individuals, with core characteristics of gradual cognitive decline and behavioral irregularities. Clinically, patients present with symptoms such as memory loss, impaired language abilities, executive dysfunction, visuospatial deficits, compromised abstract thinking, reduced computational skills, and personality changes. As the most prevalent type of dementia among elderly populations, AD accounts for 50% to 70% of all dementia cases across the globe. At present, an estimated 50 million individuals worldwide are living with this neurodegenerative condition—and with the global population aging, this number is projected to grow exponentially, reaching 110 million by 2050. Its burden on global public health and social sustainable development is becoming increasingly severe.1 After over a century of research, the pathophysiological mechanisms of AD remain incompletely clarified. Its core pathogenic features include β-amyloid (Aβ) deposition, tau hyperphosphorylation-induced neurofibrillary tangles (NFT), synaptic dysfunction, and neuronal loss, accompanied by chronic neuroinflammation, oxidative stress, and mitochondrial abnormalities, which jointly drive disease progression.2–5 Current therapeutic strategies for AD only relieve symptoms without reversing neuronal damage, with limited efficacy in middle and late stages.6,7 Stem cell therapy, featuring self-renewal, multipotent differentiation, and neuroprotective properties, provides a promising approach for root-cause treatment of AD as well as other neurodegenerative disorders.6,8,9 Among various stem cell types, HFSCs stand out as a highly promising candidate, due to their unique advantages: abundant tissue sources, minimally invasive harvesting, pluripotency, no major ethical concerns, and suitability for autologous transplantation.10–12 They overcome the limitations of other stem cell types, including ethical issues of embryonic stem cells and scarcity of neural stem cells, with low immunogenicity and strong proliferation ability.13 HFSCs have been widely studied in brain injury and neurodegenerative diseases, showing significant therapeutic potential. Neurological research on HFSCs focuses on three aspects: differentiation into neurons/glial cells for spinal cord repair,14–18 differentiation into Schwann cells for peripheral nerve repair,19–21 and secretion of VEGF to promote neovascularization.22,23 Recent studies have further demonstrated their therapeutic roles in specific brain injury and neurodegenerative diseases: in traumatic brain injury, HFSCs improve functional recovery by inhibiting neuroinflammation and promoting neurogenesis;24 in Parkinson’s disease, exosomal microRNAs derived from HFSCs alleviate disease progression by regulating α-synuclein aggregation;25 in vascular dementia, HFSCs transplantation attenuates cognitive impairment through improving cerebral blood flow.26 In AD treatment, recent studies confirm that HFSCs exert neuroprotective effects by regulating neurotrophic factors (BDNF, TGF-β) and inflammatory markers (IL-1β, IL-6, IL-10).27 Our team previously confirmed that NGF-modified HFSCs can reduce Aβ deposition and tau protein hyperphosphorylation, repair synaptic damage and improve cognitive function in rats through PI3K/Akt/GSK-3β signaling.28 However, the intrinsic therapeutic potential and specific molecular mechanisms of these naive, unmodified HFSCs in AD remain unclear—this research gap is precisely the focus of the present study. The present work tested unmodified HFSCs in AD rats for therapeutic benefit, dissected mechanisms (synaptic protection, neuronal repair, neural differentiation, microglial regulation), generated preclinical data for clinical use, and clarified the study’s value to AD research. Materials and Methods Data presented here are from a new, independent set of experiments and are not overlapping with our previous publication. The Ethical Review Board of the Second Affiliated Hospital of Harbin Medical University undertook the review and gave its official approval to all experimental protocols implemented in this research, with the assigned approval number being SYDW2022-084. HFSCs Preparation Hair follicle pads from male Sprague-Dawley (SD) rats (3–4 weeks old, 21–26 g) were dissected and digested with 0.1% collagenase IV (Gibco BRL, Gaithersburg, MD, USA) in DMEM. Hair follicles were mechanically isolated and placed into 12‑well plates (Beyotime, Shanghai, China) containing DMEM supplemented with 1% penicillin/streptomycin (Gibco) and 10% fetal bovine serum (ScienCell, Santiago, CA, USA). Cultures were kept at 37°C within a 5% CO2 humidified incubator under sterile settings. Third‑passage (P3) HFSCs were used for all subsequent experiments. For lineage differentiation, P3 HFSCs (3×104cells/cm2) were placed into 6‑well dishes. Following 24h of culture, the growth medium was replaced with either osteogenic or adipogenic differentiation medium as per the vendor’s instructions.29 The induction media were replaced every 3 days. At day 14, osteogenesis was verified by Alizarin Red staining, and adipogenesis by Oil Red O staining (both reagents from Beyotime, Shanghai, China). Chondrogenic differentiation was not attempted, as our study focuses on neural differentiation and paracrine actions in the AD context.30 Of note, the International Society for Cellular Therapy (ISCT) defines that differentiation into at least two mesenchymal lineages (osteogenic, adipogenic, or chondrogenic) is adequate for characterizing MSCs.31 For flow cytometric analysis, P3 HFSCs were harvested using trypsin, rinsed twice in PBS, and adjusted to 1×105 cells/mL. HFSCs share MSC‑like characteristics, and ISCT criteria are widely adopted for their characterization.32 We chose CD90 (ISCT‑recommended positive marker) and CD29 (a commonly used alternative MSC marker) as positive markers, along with CD45 (ISCT‑recommended negative marker) and CD31 (to rule out endothelial cell contamination), consistent with published HFSCs studies.33 Cells were stained for 60 min at ambient temperature using the following fluorochrome‑labeled antibodies: FITC‑anti‑CD29 (0.5 mg/mL; 11‑0291‑82; Thermo, Waltham, MA, USA), isophycocyanin‑anti‑CD90 (0.5 mg/mL; 14‑0900‑81; Thermo, Waltham, MA, USA), PE‑anti‑CD31 (2 mg/mL; sc‑18916; SANTA, Shanghai, China), and PE‑anti‑CD45 (5 µL/test; F3104503; Multisciences, Hangzhou, China). After incubation, cells were rinsed with PBS and suspended in 1% bovine serum albumin (BSA) prior to flow cytometric analysis (ACEA Biosciences, California, USA). Isotype controls were processed in parallel. Animals Male Sprague‑Dawley (SD) rats of clean grade, aged 6–8 weeks and weighing 200–210 g, were obtained from the Animal Experiment Center of the Second Affiliated Hospital of Harbin Medical University (license No. SCXK (Hei) 2023‑001). Sixty rats were randomly allocated into three groups (n=20): Sham+PBS, Aβ+PBS (AD+PBS) and Aβ+HFSCs (AD+HFSCs) groups (designated according to the substance injected into the hippocampus). The model of AD was established by injecting human Aβ1-42 (ab82795, Abcam, Cambridge, UK) into the hippocampus CA1 (AP-3.0 mm, L/R-2.0 mm, V-3.0 mm) after diluting it to 1mg/mL.34 Animals received intraperitoneal pentobarbital sodium for anesthesia (40 mg/kg; Shanghai Pharma, Shanghai, China) and then secured in a stereotaxic frame (RWD Life Sciences, Shenzhen, China). A 10 µL volume of Aβ1‑42 solution was delivered into each hippocampus using a microinjector (RWD Life Sciences). For the Sham group, the same volume of PBS was injected following an identical procedure. At day 14 post‑injection, rats from the sham and Aβ groups were randomly selected for Morris water maze testing. These animals were then euthanized by intraperitoneal injection of 0.3% pentobarbital sodium (150 mg/kg) and their brain tissues were processed for Congo red staining (n=3). For the AD+HFSCs group, 10 µL of HFSCs suspension containing 5×105 third‑passage cells was delivered via the same hippocampal injection route employed for Aβ1‑42 delivery (n=20). This dose was selected based on systematic evidence confirming its successful engraftment and bilateral migration in rat hippocampal injection paradigms,35 as well as dose-response studies demonstrating that low-to-moderate doses are therapeutically superior to higher doses in AD models.36 Our previous publication has confirmed the safety and efficacy of this dose in the same model. On day 21, the remaining rats in the Sham and Aβ groups received an intrahippocampal injection of 10 µL PBS (n=17). On day 34, all remaining rats underwent six days of Morris water maze training and formal testing (n=6). Following the behavioral experiment, these animals were euthanized by intraperitoneal injection of pentobarbital sodium (using the same method as before), followed by rapid decapitation to harvest the rat brains for subsequent analysis (n=3). Morris Water Maze Training was carried out on the 14th and 34th days of the experiment (Figure 1). All rats completed a 5-day place navigation task in a water maze tank with the aqueous temperature maintained at a range of 24–26°C. Each day, the rodents were carefully introduced into the water tank from four separate quadrants while facing outward, and their swimming paths as well as the time required to locate the escape platform were documented throughout each testing session. Figure 1Experimental flow chart and AD model characterization. The schedule for preparing the Sprague-Dawley rat model, treatment and behavior testing. First, Aβ1-42 or PBS was injected into the hippocampus of rats in different groups. Fourteen days later, Three rats were randomly selected from sham and Aβ group for Morris water maze test for 6 days, after that rats were sacrificed and perform Congo red staining. On the 20th day, rats were treated by HFSCs (P3) and PBS through the same needle track. On day 34, Morris water maze test were performed for 6 days. Then, behavioral all rats were sacrificed and collected the samples for following test.The flowchart illustrates the preparation and testing schedule for an Alzheimer's Disease (AD) model in rats. It begins with the establishment of AD by injecting Aβ subscript 1-42 into the hippocampus CA1 region with coordinates AP -3.0 mm, L/R -2.0 mm, V -3.0 mm. Cultivation stages P0 and P3 are shown, with identification and transplantation of HFSCs (P3) through the same route. The timeline includes: 0d - Estalish AD model via injection of Aβ1-42, 14d - Morris water maze test, 20d - Sacrifice for HE, Congo staining, 34d - Morris water maze test, 40d - Sacrifice for IHC, WB, PCR. The groups are listed as: #1 Sham+PBS n=20, #2 AD+PBS n=20, #3 AD+HFSCs n=20.Flowchart of AD model preparation and testing in rats with timelines and procedures. Experimental flow chart and AD model characterization. The schedule for preparing the Sprague-Dawley rat model, treatment and behavior testing. First, Aβ1-42 or PBS was injected into the hippocampus of rats in different groups. Fourteen days later, Three rats were randomly selected from sham and Aβ group for Morris water maze test for 6 days, after that rats were sacrificed and perform Congo red staining. On the 20th day, rats were treated by HFSCs (P3) and PBS through the same needle track. On day 34, Morris water maze test were performed for 6 days. Then, behavioral all rats were sacrificed and collected the samples for following test. Six days following the initiation of training, a spatial probe trial was performed. Following the removal of the hidden platform, every rat was gently placed starting at the quadrant directly opposite to where the escape platform had initially been located. Escape latency was calculated as the interval from when the rat entered the water until it first reached the former platform area. Additionally, the total count of crossings over the prior hidden platform was quantified and registered. Congo Red Staining Brain tissue samples were fixed, dehydrated in paraffin, sectioned, and then affixed onto microscope slides. After deparaffinization, the sections were dyed using Congo red reagent for 10 to 20 minutes, lightly dehydrated in basic ethyl alcohol, and rinsed with distilled water. Hematoxylin counterstaining was carried out for 2 minutes, followed by gentle rinsing under tap water for 1 to 2 minutes. The tissue slices were subjected to gradual dehydration using a series of ethanol solutions, rendered transparent with xylene, then coverslipped with neutral fixative medium. Images of the processed tissue slices were acquired via Nikon ECLIPSE Ti2-U optical microscope (Nikon Corporation, Tokyo, Japan). Immunohistochemical Staining To quench endogenous peroxidase, paraffin sections were exposed to 0.3% H2O2 for 30 min. Following PBS rinses, sections were blocked with normal goat serum (Beyotime; C0265) for 30 min at ambient temperature. Subsequently, they were incubated overnight at 4°C with mouse primary antibodies directed against SYP (1:200; Abways; CY5245), PSD-95 (1:200; Abways; CY5407), Iba-1 (1:200; Abcam; ab5076), DCX (1:200; Abcam; ab207175), Nestin (1:200; Proteintech; 19483-1-AP), and βIII-tubulin (1:200; Wanleibio; WL03860). The next day, sections were washed three times with PBS and then exposed to secondary antibodies for a duration of 1 hour at 37°C. Following an additional PBS rinse, immunoreactive signals were developed using a DAB substrate kit (Abcam; ab64238). The tissue slices were then hematoxylin-counterstained, dehydrated, cleared, and coverslipped. Staining outcomes were examined and documented under a light microscope. Western Blotting Assay (WB) Ice-cold lysis buffer with protease inhibitors was used to homogenize tissue samples. Centrifugation (12,000 rpm, 10 min, 4°C) yielded a supernatant that was used for BCA protein measurement. Samples (40 μg protein per lane) were resolved on 10% or 12.5% SDS-PAGE gels (Beyotime; SP0012A) at 100 V for 90–120 min. Electrophoresed proteins were transferred to PVDF membranes at 200 mA for 120 min at 4°C. Membranes were blocked (3% non-fat milk/TBST, 1 h, ambient temperature) and then incubated overnight at 4°C with primary antibodies: anti-PSD-95 (1:1000; Abcam; ab18258) and anti-SYP (1:1000; Abways; CY5273). Following three washes with TBST, membranes were incubated with HRP-conjugated secondary antibodies (1:10000; Abmart). Chemiluminescent detection was performed using ECL reagents. The experiment was run in triplicate (n=3). Images were obtained with an Omega-Lum G imaging system (ChemiScope 6300, Clinx Science Instruments, Shanghai, China). Densitometry was carried out using Image-Pro Plus software, and all values were normalized to loading controls. Reverse Transcription PCR (RT-PCR) mRNA expression of eight target genes—TNF-α, IL-1β, IL-6, IL-10, TGF-β, Arg-1, YM-1, and CD209—was measured in rat brain tissues by RT-qPCR (n=3 per group). Specifically, TRIzol reagent (Invitrogen) was used to extract total RNA. The PrimeScript RT reagent kit was employed for reverse transcription, followed by PCR amplification using the SYBR PrimeScript RT-PCR Kit II (Merck KGaA, Darmstadt, Germany) on an LC480 real-time PCR system (Roche Diagnostics, Basel, Switzerland). The sequences of all primers used are shown in Table 1.Table 1Target Gene Primer Sequences for PCRGenePrimer Sequencerat CD206 FATCTGGAGGCTGATTACGrat CD206 RGGTGTAGGCTCGGGTAGrat IL-4 FCCCTGTTCTGCTTTCTCATArat IL-4 RGTTCTCCGTGGTGTTCCTTGrat IL-6 FAGTTCCGTTTCTACCTGrat IL-6 RTCCTTAGCCACTCCTTrat TGF-β FCCCACTGATACGCCTGAGrat TGF-β RTGATCCCATTGATTTCCACrat YM-1 FCAATGTATGGGTTGGTTATrat YM-1 RAAAGTAGAAGTCAAAGGGArat Arg-1 FGCTGGCTGCTGTGGTAGrat Arg-1 RACGCATAGGTCAGGGTGrat IL-1β FTCTGTGACTCGTGGGArat IL-1β RTGTTGGCTTATGTTCTGTrat TNF-α FTTCTCATTCCTGCTCGTGGrat TNF-α RCCTCCGCTTGGTGGTTT Table 1Target Gene Primer Sequences for PCRGenePrimer Sequencerat CD206 FATCTGGAGGCTGATTACGrat CD206 RGGTGTAGGCTCGGGTAGrat IL-4 FCCCTGTTCTGCTTTCTCATArat IL-4 RGTTCTCCGTGGTGTTCCTTGrat IL-6 FAGTTCCGTTTCTACCTGrat IL-6 RTCCTTAGCCACTCCTTrat TGF-β FCCCACTGATACGCCTGAGrat TGF-β RTGATCCCATTGATTTCCACrat YM-1 FCAATGTATGGGTTGGTTATrat YM-1 RAAAGTAGAAGTCAAAGGGArat Arg-1 FGCTGGCTGCTGTGGTAGrat Arg-1 RACGCATAGGTCAGGGTGrat IL-1β FTCTGTGACTCGTGGGArat IL-1β RTGTTGGCTTATGTTCTGTrat TNF-α FTTCTCATTCCTGCTCGTGGrat TNF-α RCCTCCGCTTGGTGGTTT Target Gene Primer Sequences for PCR Nissl Staining Frozen hippocampal sections (n=3) were removed from −80°C storage and thawed at ambient temperature. After washing with deionized water to eliminate residual OCT compound (Sakura Finetek, Torrance, USA), sections were gently blotted dry. Nissl staining solution was then applied, and sections were incubated for 10 min at ambient temperature. Following two deionized water rinses, sections were dipped briefly (5 sec) in 95% ethanol, then dehydrated twice in fresh 95% ethanol (2 min each). Sections were cleared in xylene (5 min), then coverslipped using neutral mounting medium, and examined under a light microscope for Nissl body staining. Statistical Analysis All experimental outcomes are expressed as mean ± standard deviation (SD). ImageJ software was utilized for the quantification of optical density, whereas GraphPad Prism version 9.5 was applied for statistical computations and graph generation. Single-factor analysis of variance (ANOVA) coupled with Tukey’s post-test was utilized to compare differences among various cohorts. Statistical significance was defined as a P value below 0.05 (*P < 0.05, **P < 0.01, ***P < 0.001,****P < 0.0001). Results Successful Preparation and Identification of HFSCs HFSCs were extracted from the upper lip hair follicle pads of male SD rats and cultured until the third passage for use in subsequent experimental procedures (Figure 2A). To confirm the multipotent capacity of these cells, osteogenic and adipogenic differentiation were induced. Following osteogenic induction, HFSCs developed into osteoblast-like cells, which exhibited positive staining when treated with alizarin red (Figure 2B). In the case of adipogenic differentiation, Oil Red O staining identified orange lipid droplets within the cytoplasm of HFSCs, which confirmed that these cells had differentiated into adipocytes (Figure 2C). Analysis of cell surface antigens via flow cytometry (Figure 2D) revealed robust expression of the mesenchymal stem cell-specific markers CD29 and CD90, while the endothelium-specific marker CD31 and hematopoietic lineage-specific marker CD45 exhibited low expression levels. Figure 2Results of isolation, culture, and identification of HFSCs from the bulge region of hair follicles and the ability of HFSCs to poly-differentiate. Optical microscopy of an intact hair follicle, microdissected and extracted from the hair follicle in the bulge region for primary cell culture. (A) HFSCs in primary, P1, and P3 were under an optical microscope, scale bar=50μm. After 14 days of culture, osteogenic and adipogenic differentiation was confirmed by alizarin red (B) and oil Red O staining (C). (D) Flow cytometry detection of HFSCs surfaces positive markers CD29, CD90, negative markers CD31, CD45. A, C scale bar=25μm, B scale bar=50μm.Image A displays three micrographs (P0, P1, P3) with 25 µm scale bars. P0 has scattered cells and a hair follicle-like structure; P1 shows denser elongated cells; P3 presents a uniform field of elongated cells. Image B features a stained microscopy field with a 50 µm scale bar and numerous stained deposits. Image C shows stained cells with rounded droplets and a 25 µm scale bar. Image D includes four flow cytometry histograms with fluorescence intensity on logarithmic x-axes and event counts on y-axes, marked with positivity gates. Histogram 1 (CD29) ranges from 10^1 to 10^7, counts 0-300, FITC+ 85.8%. Histogram 2 (CD90) ranges from 10^1 to 10^7, counts 0-200, FITC+ 82.8%. Histogram 3 (CD45) ranges from 10^1 to 10^7, counts 0-100, APC+ 0.060%. Histogram 4 (CD31) ranges from 10^1 to 10^7, counts 0-250, PE+ 0.13%. High positivity is noted for CD29 and CD90, while CD45 and CD31 show near-zero positivity.A multi-part figure showing HFSC microscopy, staining and flow histograms with high CD29 and CD90 positivity. Results of isolation, culture, and identification of HFSCs from the bulge region of hair follicles and the ability of HFSCs to poly-differentiate. Optical microscopy of an intact hair follicle, microdissected and extracted from the hair follicle in the bulge region for primary cell culture. (A) HFSCs in primary, P1, and P3 were under an optical microscope, scale bar=50μm. After 14 days of culture, osteogenic and adipogenic differentiation was confirmed by alizarin red (B) and oil Red O staining (C). (D) Flow cytometry detection of HFSCs surfaces positive markers CD29, CD90, negative markers CD31, CD45. A, C scale bar=25μm, B scale bar=50μm. Successful Establishment of the AD Rat Model Rats assigned to distinct groups were given stereotaxic injections of Aβ1–42 (to establish the AD model) or PBS (for the Sham group) into the CA1 area of the hippocampus. Two weeks after the injection, three rats were chosen at random from both the Sham and Aβ groups to undergo Morris water maze testing and Congo red staining for model validation. Outcomes showed that the Aβ group needed significantly longer durations to locate the concealed platform in comparison with Sham counterparts (Figure 3A). Figure 3Established AD rat model and identification successfully. (A) The escape latency time for each group to escape in the location navigation exam. (B and C) In the spatial probe test, the numbers of platform crossing and time in the target section in each group. (D) Aβ deposition were detected in the rats hippocampus CA1 of sham and Aβ groups by Congo red, scale bars: 50μm. (E) Quantitative assessment of Congo red stained plaque number in 2 groups. ***P <0.001, ****P < 0.0001, ns, not significant. n=3.Image A: Line graph with error bars. X-axis: DAY (0-6), Y-axis: Escape Latency (sec, 0-100). Legend: Control, Sham, Abeta. Control: Day 1 ~65 sec, Day 5 ~15 sec. Sham: Day 1 ~70 sec, Day 5 ~16 sec. Abeta: Day 1 ~82 sec, Day 5 ~60 sec. Image B: Bar chart. X-axis: Control, Sham, Abeta. Y-axis: Crossing platform times (0-8). Heights: Control ~5.5, Sham ~4.8, Abeta ~1.5. Significance: Control vs Sham (ns), Sham vs Abeta (****), Control vs Abeta (****). Image C: Bar chart. X-axis: Control, Sham, Abeta. Y-axis: Time in target section (sec, 0-50). Heights: Control ~34 sec, Sham ~33 sec, Abeta ~16 sec. Significance: Control vs Sham (ns), Sham vs Abeta (***), Control vs Abeta (***). Image D: Micrographs labeled Sham and Abeta, scale 50 micrometers. Image E: Bar chart. X-axis: Sham, Abeta. Y-axis: Congo Red positive amyloid plaques (0-25). Heights: Sham ~1, Abeta ~17. Significance: (***).A composite figure with 3 graphs, 2 micrographs and 1 bar chart on Control, Sham and Abeta rats. Established AD rat model and identification successfully. (A) The escape latency time for each group to escape in the location navigation exam. (B and C) In the spatial probe test, the numbers of platform crossing and time in the target section in each group. (D) Aβ deposition were detected in the rats hippocampus CA1 of sham and Aβ groups by Congo red, scale bars: 50μm. (E) Quantitative assessment of Congo red stained plaque number in 2 groups. ***P <0.001, ****P < 0.0001, ns, not significant. n=3. During the spatial probe test, the Aβ group displayed fewer passes over the previous platform position (Figure 3B) and spent a shorter duration within the target quadrant relative to the Sham group (Figure 3C). Congo red staining of hippocampal slices further verified obvious Aβ plaque accumulation in Aβ-treated rats, while barely any Aβ deposition was detected in Sham counterparts (Figure 3D and E). HFSCs Transplantation Improved Cognitive Impairment of AD Rats To assess whether HFSCs transplantation could reverse behavioral impairments in AD rats, Morris water maze evaluations were conducted at 2 weeks post transplantation. Throughout the 5-day training period, rats transplanted with HFSCs demonstrated a progressive enhancement in their capability to locate the hidden platform (Figure 4). Relative to the AD+PBS group, rats in the HFSCs transplantation group exhibited notably shorter escape latencies (Figure 4A). During the spatial probe test, the HFSCs-transplanted group displayed more frequent passes over the prior platform location (Figure 4B) and spent a considerably longer duration within the former platform quadrant compared with the AD+PBS group (Figure 4C). Furthermore, analysis of swimming paths on day 6 of the probe test uncovered clear differences between the three groups: rats transplanted with HFSCs employed more focused search tactics to find the former platform area (Figure 4D). Together, these findings illustrate that HFSCs transplantation effectively mitigates cognitive deficits in AD rats. Figure 4HFSCs improve cognitive impairment of AD rat. (A) The escape latency time of each group in the place navigation test. In the spatial probe test, the numbers of platform crossing (B) and time in the target section (C). (D) Representative tracks of the spatial probe test on day6. When compared with the AD+PBS group rats, the rats transplanted with HFSCs improved strategies to reach the platform significantly. *P < 0.05, **P < 0.01, ****P < 0.0001, n=6.Image A: Line graph with y-axis 'Escape Latency (sec)' and x-axis 'DAY' (0-6). Legend: Sham+PBS, AD+PBS, AD+HFSCs. Data points (Day 1-5): Sham+PBS (70, 50, 32, 25, 15), AD+PBS (85, 78, 68, 67, 57), AD+HFSCs (78, 72, 58, 47, 34). Image B: Bar chart with y-axis 'Crossing platform times' and categories Sham+PBS, AD+PBS, AD+HFSCs (0-8). Bar heights: Sham+PBS (5.2), AD+PBS (0.9), AD+HFSCs (2.3). Significance marked with asterisks. Image C: Bar chart with y-axis 'Time in target section (sec)' and categories Sham+PBS, AD+PBS, AD+HFSCs (0-50). Bar heights: Sham+PBS (33), AD+PBS (14), AD+HFSCs (22). Significance marked with asterisks. Image D: Swim-track plots for Sham+PBS, AD+PBS, AD+HFSCs, each circle divided by quadrants (NW-II, NE-I, SW-III, SE-IV) with track line and platform location marked.A mixed figure showing one line graph, two bar charts and three Morris water maze track plots. HFSCs improve cognitive impairment of AD rat. (A) The escape latency time of each group in the place navigation test. In the spatial probe test, the numbers of platform crossing (B) and time in the target section (C). (D) Representative tracks of the spatial probe test on day6. When compared with the AD+PBS group rats, the rats transplanted with HFSCs improved strategies to reach the platform significantly. *P < 0.05, **P < 0.01, ****P < 0.0001, n=6. HFSCs Transplantation Reduced Synaptic Protein Impairment Among the diverse pathological alterations present in the cerebral tissue of individuals with AD, accumulating evidence indicates that synaptic degeneration exhibits the strongest correlation with cognitive deterioration.37 To evaluate the protective role of HFSCs in synaptic function, hippocampal levels of SYP and PSD-95 were examined by immunohistochemical staining and Western blot assays (Figure 5 and Figure6). Through immunohistochemical examination, the AD+PBS group showed a marked decline in the average optical density (AOD) values of both SYP and PSD-95 relative to the Sham+PBS group. In contrast, HFSCs transplantation markedly elevated the expression levels of both SYP (Figure 5A and B) and PSD-95 (Figure 6A and B). Western blot analysis further confirmed this protective effect, showing that HFSCs transplantation reversed the Aβ-induced reduction in SYP and PSD-95 protein levels (Figure 5C and D; Figure 6C and D). Figure 5HFSCs transportation increased the level of SYP protein expression. (A) Immunohistochemical staining results of SYP protein expression in each groups rats CA1 stratum radiatum. (B) The AOD of SYP protein expression of each group. (C) The level of SYP protein expression was quantified by Western blot analysis in 3 groups rats hippocampus, respectively. (D) The relative quantification of protein expression. *P < 0.05, **P < 0.01, ****P < 0.0001, n=3.The image A shows immunohistochemical staining of SYP protein expression in three groups: Sham+PBS, AD+PBS and AD+HFSCs. The magnified sections highlight differences in staining intensity. Image B is a bar graph showing the average optical density (AOD) of SYP protein, with significant differences indicated by asterisks: < 0.05, < 0.01. Image C displays Western blot results for SYP and β-Tubulin proteins across the three groups. Image D is a bar graph illustrating relative SYP protein expression, with significant differences marked by asterisks: * < 0.0001. The data suggest increased SYP expression in the AD+HFSCs group compared to AD+PBS.Comparison of SYP protein expression in Sham+PBS, AD+PBS and AD+HFSCs groups. Figure 6HFSCs transportation increased the level of PSD-95 protein expression. (A) Immunohistochemical staining results of PSD-95 protein expression in each groups CA1 area. (B) The AOD of PSD-95 protein in CA1 area. (C) The level of PSD-95 protein expression was quantified by Western blot analysis in 3 groups rats hippocampus, respectively. (D) The relative quantification of protein expression. *P < 0.05, **P < 0.01, ***P <0.001, ****P < 0.0001, n=3.Image A displays PSD95 protein staining in CA1 for Sham+PBS, AD+PBS and AD+HFSCs groups. Each has a micrograph with a boxed region and a magnified view, scale bar at 50 micrometers. Image B shows a bar chart of PSD95 protein AOD: Sham+PBS at 0.18, AD+PBS at 0.12, AD+HFSCs at 0.14. Significance: Sham+PBS vs AD+PBS (****), Sham+PBS vs AD+HFSCs (***), AD+PBS vs AD+HFSCs (*). Image C presents a Western blot with lanes for Sham+PBS, AD+PBS, AD+HFSCs, showing PSD95 and beta Actin, molecular weights 85 kDa and 43 kDa respectively. Image D features a bar chart of Relative PSD95 protein expression: Sham+PBS at 1.0, AD+PBS at 0.3, AD+HFSCs at 0.6. Significance: Sham+PBS vs AD+PBS (***), Sham+PBS vs AD+HFSCs (**), AD+PBS vs AD+HFSCs (*).Four-part figure of PSD95 expression showing reduced AD plus PBS and partial recovery with AD plus HFSCs. HFSCs transportation increased the level of SYP protein expression. (A) Immunohistochemical staining results of SYP protein expression in each groups rats CA1 stratum radiatum. (B) The AOD of SYP protein expression of each group. (C) The level of SYP protein expression was quantified by Western blot analysis in 3 groups rats hippocampus, respectively. (D) The relative quantification of protein expression. *P < 0.05, **P < 0.01, ****P < 0.0001, n=3. HFSCs transportation increased the level of PSD-95 protein expression. (A) Immunohistochemical staining results of PSD-95 protein expression in each groups CA1 area. (B) The AOD of PSD-95 protein in CA1 area. (C) The level of PSD-95 protein expression was quantified by Western blot analysis in 3 groups rats hippocampus, respectively. (D) The relative quantification of protein expression. *P < 0.05, **P < 0.01, ***P <0.001, ****P < 0.0001, n=3. HFSCs Transportation Ameliorated Neuronal Damage To assess neuronal damage in the AD rat hippocampus, we performed Nissl body staining on tissue sections collected after Morris water maze test. Representative images from each group are shown in Figure 7. HFSCs treatment reduced neuronal injury in the hippocampal CA1 region compared to AD controls. Figure 7HFSCs transplantation ameliorated neuronal damage. (A) Nissl body staining of hippocampal vertebral cells in each group: the number and volume of Nissl bodies in hippocampal vertebral cells of rats in Sham+PBS group were more and larger, while the number of Nissl bodies in the AD+PBS group was less, with light staining and neuronal damage. However, these lesions were improved after HFSCs transplantation. (B) The quantification analysis of Nissl body stain positive area (Inches2). Scale bars: 100μm, ***P <0.001, ****P < 0.0001, ns, not significant. n=3.The image A showing three side-by-side micrographs labeled Sham+PBS, AD+PBS and AD+HFSCs, each with a scale bar. The Sham+PBS micrograph shows a dense band of Nissl-stained cells. The AD+PBS micrograph shows fewer Nissl-stained cells and lighter staining. The AD+HFSCs micrograph shows more Nissl-stained cells than AD+PBS. The image B showing a bar chart titled Nissl body stain positive area (Inches squared). The x-axis categories are Sham+PBS, AD+PBS and AD+HFSCs. The y-axis tick labels are 0, 50000, 100000, 150000 and 200000. The Sham+PBS bar is near 150000, the AD+PBS bar is near 100000 and the AD+HFSCs bar is near 145000. Significance brackets show Sham+PBS versus AD+PBS marked with four dots, AD+PBS versus AD+HFSCs marked with three dots and Sham+PBS versus AD+HFSCs marked ns.A multi-panel figure of hippocampal Nissl staining micrographs and a bar chart across three groups. HFSCs transplantation ameliorated neuronal damage. (A) Nissl body staining of hippocampal vertebral cells in each group: the number and volume of Nissl bodies in hippocampal vertebral cells of rats in Sham+PBS group were more and larger, while the number of Nissl bodies in the AD+PBS group was less, with light staining and neuronal damage. However, these lesions were improved after HFSCs transplantation. (B) The quantification analysis of Nissl body stain positive area (Inches2). Scale bars: 100μm, ***P <0.001, ****P < 0.0001, ns, not significant. n=3. HFSCs Transplantation Promoted Neurogenesis To determine if HFSCs are capable of promoting neurogenesis in the brains of AD rats, immunohistochemical staining was employed to assess neuronal differentiation within the hippocampal dentate gyrus (DG) across all three experimental groups. Three commonly utilized markers were chosen for this analysis: DCX (an indicator of neural precursor cells/immature neurons),38 Nestin (a hallmark of neural stem cells),39 and βIII-Tubulin (a signature of neural skeleton microtubulin).40 IHC staining targeting DCX disclosed a pronounced decrease in DCX‑immunoreactive cells within the DG of AD rats, as compared with Sham+PBS rats. After HFSCs transplantation, a marked rise in DCX‑positive neurons was detected (Figure 8A and D). We also measured the average optical density (AOD) of Nestin and βIII-Tubulin positive cells in the DG region. Relative to Sham counterparts, the AD group exhibited notably decreased AOD values for these two markers. Nevertheless, HFSCs treatment reversed this tendency, resulting in a notable rise in the AOD values of Nestin and βIII-Tubulin positive cells in AD rats (Figure 8B, C, E and F). Figure 8HFSCs transplantation promotes neurogenesis. (A–C) Immunohistochemical staining results of DCX, Nestin and βIII-Tubulin in DG region of 3 groups, respectively. (D–F) The number of DCX and AOD of Nestin and βIII-Tubulin positive cells in DG area. Scale bar = 100μm. *P < 0.05, **P < 0.01, ***P <0.001, ****P < 0.0001, n=3.The image A showing immunohistochemical staining results for DCX in the DG region across three groups: Sham+PBS, AD+PBS and AD+HFSCs. The image B showing Nestin staining in the same groups. The image C showing βIII-Tubulin staining. The image D showing a bar graph of the number of DCX positive cells in the DG, with Sham+PBS having the highest count, followed by AD+HFSCs and AD+PBS. The image E showing a bar graph of the average optical density (AOD) of Nestin positive cells, with Sham+PBS having the highest AOD, followed by AD+HFSCs and AD+PBS. The image F showing a bar graph of the AOD of βIII-Tubulin positive cells, with Sham+PBS having the highest AOD, followed by AD+HFSCs and AD+PBS. Statistical significance is indicated with asterisks: < 0.05, < 0.01, < 0.001, < 0.0001.Immunohistochemical results of DCX, Nestin, βIII-Tubulin in DG region across three groups. HFSCs transplantation promotes neurogenesis. (A–C) Immunohistochemical staining results of DCX, Nestin and βIII-Tubulin in DG region of 3 groups, respectively. (D–F) The number of DCX and AOD of Nestin and βIII-Tubulin positive cells in DG area. Scale bar = 100μm. *P < 0.05, **P < 0.01, ***P <0.001, ****P < 0.0001, n=3. HFSCs Transportation Alleviated the Excessive Activation of Microglia Previous studies have demonstrated that HFSCs transplantation attenuated microglial activation as well as the generation of proinflammatory cytokines in ischemic/reperfused brain tissue.41 This prompted us to investigate whether HFSCs transplantation could similarly modulate microglial activity during the initial phases of AD pathogenesis. IHC staining was performed to quantify the population of Iba‑1‑immunoreactive cells, the specific marker for microglia,42 in the hippocampal region. As presented in Figure 9A and B, AD rats treated with HFSCs displayed markedly fewer Iba-1-immunoreactive cells than the PBS-treated AD group (P <0.05). We then performed qPCR assays to evaluate the transcriptional profiles of major proinflammatory and anti‑inflammatory molecules. These findings indicated that the transcript levels of TNF-α, IL-1β, and IL-6 were markedly elevated in PBS-injected AD rats than in PBS-injected Sham rats. In contrast, HFSCs transplantation significantly downregulated the levels of these proinflammatory mediators among AD rats (P <0.05). Notably, the mRNA expression of IL-10 and TGF-β, which serve as negative regulators of inflammatory reactions, was obviously upregulated following HFSCs engraftment (P < 0.05) (Figure 10A). Figure 9HFSCs transportation alleviated the excessive activation of microglia. (A) Immunohistochemical staining of Iba1 in 3 groups rats hippocampus, respectively. (B) Statistical results of numbers of Iba1 positive cells per mm2 in different group. Scale bar=100μm. *P < 0.05, **P < 0.01, ***P <0.001, n=3.Image A shows immunohistochemical staining of Iba1 in hippocampus tissue from three groups: Sham + PBS, AD + PBS and AD + HFSCs. Each column displays a tissue micrograph with a magnified inset of the boxed region, revealing dark-stained Iba1 positive cells. A scale bar indicates 100 micrometers. AD + PBS tissue visibly contains more dark-stained cells than the other two groups. Image B is a bar chart. The x-axis lists three groups: Sham + PBS, AD + PBS and AD + HFSCs. The y-axis is labeled the number of Iba1 positive cells per mm squared, ranging from 0 to 400. Approximate bar values are 130 for Sham + PBS, 330 for AD + PBS and 200 for AD + HFSCs. AD + PBS shows the highest count. AD + HFSCs is reduced compared to AD + PBS but remains above Sham + PBS. Significance brackets are marked with three asterisks between Sham + PBS and AD + PBS, two asterisks between AD + PBS and AD + HFSCs and one asterisk between Sham + PBS and AD + HFSCs. n equals 3.Iba1 micrographs and bar chart of Iba1+ cells/mm² in three rat groups. Figure 10HFSCs transportation declined neuroinflammation. HFSCs transplantation promoted Microglia transform to M2 and attenuated neuroinflammation. (A) The degree of inflammatory and anti-inflammatory factors’ mRNA expression were analyzed by RT-PCR in each group. (B) The mRNA expression level of M2 markers were analyzed by RT-PCR in each group. *P < 0.05, **P < 0.01, ***P <0.001, ****P < 0.0001, n=3.The image A showing a grouped bar graph. Legend lists Sham plus P B S, A D plus P B S and A D plus H F S C s. X axis categories: T N F dash alpha, I L dash 1 beta, I L dash 6, I L dash 10, T G F dash beta. Y axis label: m R N A Expression Level, range 0 to 5. Bar heights: T N F dash alpha about 1.0, 3.0, 2.0; I L dash 1 beta about 1.0, 3.5, 2.4; I L dash 6 about 1.0, 4.0, 2.7; I L dash 10 about 1.0, 0.6, 0.8; T G F dash beta about 1.0, 0.3, 0.6. Brackets with asterisks appear above each category. The image B showing a grouped bar graph. X axis categories: I L dash 4, I L dash 10, Arg dash 1, Y M dash 1, C D 206. Y axis label: m R N A Expression Level, range 0 to 1.5. Bar heights: I L dash 4 about 1.0, 0.45, 0.70; I L dash 10 about 1.0, 0.55, 0.75; Arg dash 1 about 1.0, 0.40, 0.60; Y M dash 1 about 1.0, 0.35, 0.60; C D 206 about 1.0, 0.50, 0.75. Brackets with asterisks appear above each category.A grouped bar graph showing messenger ribonucleic acid expression levels across treatment groups. HFSCs transportation alleviated the excessive activation of microglia. (A) Immunohistochemical staining of Iba1 in 3 groups rats hippocampus, respectively. (B) Statistical results of numbers of Iba1 positive cells per mm2 in different group. Scale bar=100μm. *P < 0.05, **P < 0.01, ***P <0.001, n=3. HFSCs transportation declined neuroinflammation. HFSCs transplantation promoted Microglia transform to M2 and attenuated neuroinflammation. (A) The degree of inflammatory and anti-inflammatory factors’ mRNA expression were analyzed by RT-PCR in each group. (B) The mRNA expression level of M2 markers were analyzed by RT-PCR in each group. *P < 0.05, **P < 0.01, ***P <0.001, ****P < 0.0001, n=3. Further quantification was performed to measure the transcript levels of M2-type microglial surface markers (Figure 10B). The results demonstrated that HFSCs transplantation upregulated the expression of Arg-1, YM-1, CD206, IL-10, and IL-4 in M2-type microglial cells. This indicates that HFSCs can drive microglial phenotypic switching toward an M2‑like anti‑inflammatory state, thereby boosting the production of inflammation‑resolving factors. Collectively, these findings suggest that HFSCs transplantation alleviates neuroinflammation in AD model rats. Discussion AD pathology includes amyloid plaques, neurofibrillary tangles, widespread neuronal loss, and synaptic damage across multiple brain regions. Stem cell transplantation represents a potential avenue for AD therapy. Our team previously reported that NGF‑modified HFSCs improved cognitive performance in AD rats.28 With advances in genetic engineering, stem cells engineered to overexpress specific factors can augment the reparative capacity of their native counterparts. This enhanced potential arises from multiple mechanisms, such as better survival and differentiation of transplanted cells, reduced apoptosis, and increased neovascularization or functional recovery.43 The present study, however, focuses on naive (unmodified) HFSCs for the treatment of AD model rats. This study sought to elucidate how HFSCs influence AD‑like behaviors in a rat model of Aβ injection. We found that stereotaxic hippocampal delivery of HFSCs ameliorated these behavioral deficits, as evidenced by progressively improved Morris water maze performance. Within the AD brain, excessive Aβ generation and amyloid plaque build-up shorten the lifespan of newborn nerve cells and suppress neurogenesis in the hippocampus.44 Following HFSCs administration, the number and staining intensity of Nissl bodies in CA1 region of AD rats were improved, this indicates that HFSCs transplantation ameliorated CA1 pyramidal neurons loss and neuronal damage. Moreover, the IHC results of DCX, Nestin and βIII-Tubulin exhibited a decline in AD+PBS group, suggesting that neurotoxic proteins inhibited hippocampal neurogenesis. Our results demonstrated that HFSCs could promote neurogenesis, which was compromised by amyloid plaque and associated damage. Earlier work has reported that stem cells rescue memory deficits in AD rats via similar pathways.44 Synaptic proteins are key building blocks of synaptic architecture and critically regulate neurotransmitter release and plasticity.45 Their expression levels thus reflect synaptic plasticity, especially long‑term potentiation (LTP). These proteins fall into presynaptic and postsynaptic categories. Soluble Aβ and tau directly poison synapses, disrupting synaptic proteins and driving cognitive decline.46 Our results agree with previous reports that mesenchymal stem cell transplantation attenuates synapse‑related injury and memory deficits in AD rats.47,48 HFSCs appear to safeguard synapses through two routes: lowering Aβ/tau hyperphosphorylation to reduce toxicity and restore LTP, and stimulating the PI3K/Akt/Wnt/β‑catenin pathway to boost plasticity and cognition.49 Recent studies have shown that HFSCs secrete multiple neuroprotective factors,50 which likely accounts for the progressive behavioral improvement seen in HFSC‑treated rats. Tang et al further demonstrated that HFSCs modulate astrocyte activation via paracrine cytokines, including TGF‑β and IL‑4.51 Neuroinflammation is considered a major driver of AD pathology.52–55 In neurodegenerative states, CNS glia (microglia and astrocytes) become activated. To assess whether transplanted HFSCs influence microglial cells in the AD rat brain, we performed microglial labeling. Immunohistochemistry revealed more activated microglial cells in the AD+PBS group than in the Sham+PBS controls. HFSCs transplantation suppressed this over‑activation in the hippocampus. Additional experiments confirmed that HFSCs not only inhibit microglial overactivity but also promote their transition toward a neuroprotective (M2) phenotype, enhancing the secretion of neuroprotective factors and dampening CNS inflammation. The observed anti‑inflammatory and pro‑neurogenic effects strongly support the idea that HFSCs exert their therapeutic benefits, at least in part, via paracrine signaling. Consistent with this, CX3CL1‑Wnt3a‑MSC transplantation ameliorated cognitive impairment in AD rats via modulating microglia‑driven neuroinflammation.46 HFSCs have attracted considerable interest due to their easy accessibility, high proliferative capacity, and broad differentiation potential.56,57 They also exhibit strong neurogenic and neurotrophic properties.22,58 In rat models of spinal cord trauma, implanted HFSCs survived and expanded at the lesion site. These grafted cells gave rise to glial subtypes (eg, astrocytes and oligodendrocytes) as well as neurons. Of note, oligodendrocytes facilitated remyelination around both spared and injured axons. Moreover, HFSCs expressed neurotrophic factors and other trophic molecules, which together supported nerve healing and boosted recovery of function.58 In ischemic rats, HFSCs grafting markedly attenuated microglial activation, suppressed inflammatory responses, improved blood‑brain barrier integrity, and lessened brain swelling. It also boosted neuronal survival and enhanced microvascular density in the brain.50 Comparison with our previous study28 using NGF-modified HFSCs reveals distinct mechanisms. While the prior study focused on anti-amyloid and anti-tau effects via PI3K/Akt/GSK-3β pathway activation, the present work demonstrates three novel intrinsic properties of unmodified HFSCs: promotion of endogenous neurogenesis (increased DCX, Nestin, and βIII-Tubulin in the DG); protection of synaptic proteins (restoration of SYP and PSD-95); and modulation of microglial M1-to-M2 polarization (reduced TNF-α, IL-1β, IL-6; increased Arg-1, YM-1, CD206, IL-10, IL-4). Overall, these findings suggest that HFSCs transplantation is an effective approach to reverse behavioral impairments in AD, operating through multi-target mechanisms including neuronal protection, neurogenesis, synaptic preservation, and neuroinflammation suppression, as summarized in Figure 11. With over five million hair follicles per adult, HFSCs offer a plentiful, accessible, and clinically viable option for AD treatment.57 Figure 11Overview diagram of the mechanism of HFSCs treatment on AD rats. Schematic illustration showing the proposed therapeutic mechanisms of naive HFSCs transplantation in AD rats. HFSCs transplantation reduces tau hyperphosphorylation and PHFs/NFTs formation [↓], attenuates Aβ oligomer-induced neuronal toxicity [↓], promotes endogenous neurogenesis (DCX, Nestin, βIII-Tubulin) [↑], restores synaptic proteins SYP and PSD-95 [↑], and modulates microglial M1-to-M2 polarization (pro-inflammatory cytokines TNF-α, IL-1β, IL-6 [↓]; anti-inflammatory factors IL-10, TGF-β and M2 markers Arg-1, YM-1, CD206 [↑]). These multi-target effects collectively reduce neuronal damage [↓], attenuate neuroinflammation [↓], and improve cognitive function [↑].The image illustrates the mechanism of HFSCs treatment on AD rats. HFSCs transplantation is shown to reduce tau hyperphosphorylation, paired helical filaments and neurofibrillary tangles formation. Aβ oligomers are depicted causing neuronal toxicity, which is mitigated by HFSCs. Microglia are shown with arrows indicating decreased inflammatory factors and increased anti-inflammatory factors. Synaptic plasticity is enhanced and neuronal damage is reduced, promoting endogenous neurogenesis. The diagram highlights multi-target effects, including modulation of microglial polarization and restoration of synaptic proteins, contributing to improved cognitive function.HFSCs treatment in AD rats reduces tau hyperphosphorylation, Aβ toxicity and boosts neurogenesis. Overview diagram of the mechanism of HFSCs treatment on AD rats. Schematic illustration showing the proposed therapeutic mechanisms of naive HFSCs transplantation in AD rats. HFSCs transplantation reduces tau hyperphosphorylation and PHFs/NFTs formation [↓], attenuates Aβ oligomer-induced neuronal toxicity [↓], promotes endogenous neurogenesis (DCX, Nestin, βIII-Tubulin) [↑], restores synaptic proteins SYP and PSD-95 [↑], and modulates microglial M1-to-M2 polarization (pro-inflammatory cytokines TNF-α, IL-1β, IL-6 [↓]; anti-inflammatory factors IL-10, TGF-β and M2 markers Arg-1, YM-1, CD206 [↑]). These multi-target effects collectively reduce neuronal damage [↓], attenuate neuroinflammation [↓], and improve cognitive function [↑]. This work has certain limitations. One concern is that the rodent model of AD, while capturing some key pathological features of the disease, cannot fully replicate the complexity and heterogeneity of AD in humans. Additionally, our investigation focused on short-term therapeutic effects, and the long-term outcomes, including the fate of transplanted HFSCs in the brain, require further study. Second, while we observed significant therapeutic effects, the precise molecular mechanisms, particularly the specific paracrine factors involved, remain to be fully elucidated. Furthermore, the intracranial injection route used in this preclinical study is invasive and not directly translatable to clinical practice. Conclusions In this study, we found that HFSCs transplantation attenuated synaptic protein damage and neuronal loss, promoted neurogenesis, and suppressed neuroinflammation in AD rats. These findings further enrich the preclinical evidence regarding the neuroprotective role of naive HFSCs in AD pathogenesis. Compared with our prior research focusing on NGF-modified HFSCs, the present study using naive HFSCs provides independent and complementary evidence for the potential of HFSC-based therapy in AD. Overall, HFSCs appear to be a safe and promising candidate for AD treatment. Future work will aim to address the limitations of the current study and advance clinical translation. This includes: 1. Optimizing delivery strategies: Exploring clinically feasible, minimally invasive routes (eg, intravenous infusion, intranasal administration) to replace intracranial injection. 2. Validating efficacy and safety in complex models: Validating efficacy and safety in non-human primates to bridge the gap between rodent studies and human application. 3. Elucidating precise mechanisms: Clarifying the neuroprotective mechanisms of naive HFSCs, including specific paracrine factors and signaling pathways. 4. Addressing translational challenges: Determining optimal therapeutic doses for humans, ensuring long-term safety (immune reactions, tumorigenicity), and establishing scalable manufacturing protocols for clinical-grade HFSCs.